Publisher's Synopsis
This program examines the changing usage patterns of the atypical antipsychotics since their introduction and correlates these with new data on discharge and remission rates. Dr. Love describes the difficulties inherent in pharmacoeconomic studies and outlines points to be considered by practitioners seeking to draw conclusions from the literature. He reviews techniques that can be employed to maximize outcomes while minimizing costs. He illuminates the impact of dosage on therapeutic and/or adverse effects, and the pharmacoeconomic variables that affect cost effectiveness.
